Shares of Teladoc, Inc. (NYSE:TDOC) have received a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $38.00.

Several research firms have issued reports on TDOC. BidaskClub raised Teladoc from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $42.00 price objective on shares of Teladoc in a report on Friday, July 28th. KeyCorp reaffirmed a “buy” rating and set a $37.00 price objective on shares of Teladoc in a report on Sunday, September 17th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $31.00 price objective on shares of Teladoc in a report on Tuesday, September 26th. Finally, Zacks Investment Research raised Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, September 21st.

COPYRIGHT VIOLATION NOTICE: “Teladoc, Inc. (TDOC) Receives Average Recommendation of “Buy” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/26/teladoc-inc-tdoc-receives-average-recommendation-of-buy-from-analysts.html.

Teladoc (TDOC) opened at 32.00 on Thursday. Teladoc has a 12 month low of $14.00 and a 12 month high of $37.55. The firm’s market capitalization is $1.81 billion. The stock’s 50 day moving average price is $33.27 and its 200 day moving average price is $33.27.

Teladoc (NYSE:TDOC) last announced its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $44.60 million during the quarter, compared to analyst estimates of $44.39 million. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The firm’s revenue was up 68.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.38) earnings per share. Equities research analysts expect that Teladoc will post ($1.46) earnings per share for the current fiscal year.

In other Teladoc news, VP Mark Hirschhorn sold 25,000 shares of the company’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $31.93, for a total transaction of $798,250.00. Following the completion of the sale, the vice president now owns 64,987 shares in the company, valued at approximately $2,075,034.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Adam C. Vandervoort sold 53,806 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.92, for a total transaction of $1,663,681.52. Following the sale, the insider now owns 33,008 shares of the company’s stock, valued at approximately $1,020,607.36. The disclosure for this sale can be found here. Insiders have sold a total of 168,806 shares of company stock valued at $5,430,382 in the last quarter. Corporate insiders own 4.47% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. raised its position in shares of Teladoc by 125.7% during the 1st quarter. Ameriprise Financial Inc. now owns 131,493 shares of the health services provider’s stock valued at $3,288,000 after acquiring an additional 73,231 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Teladoc by 22.2% during the 2nd quarter. Alliancebernstein L.P. now owns 2,793,590 shares of the health services provider’s stock valued at $96,938,000 after acquiring an additional 507,390 shares during the last quarter. Swiss National Bank raised its position in shares of Teladoc by 37.5% during the 1st quarter. Swiss National Bank now owns 56,800 shares of the health services provider’s stock valued at $1,420,000 after acquiring an additional 15,500 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Teladoc during the 2nd quarter valued at $58,287,000. Finally, Riverbridge Partners LLC bought a new stake in shares of Teladoc during the 2nd quarter valued at $23,392,000.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.